298 results on '"Merola, Joseph F."'
Search Results
2. Mental health outcomes in patients with moderate to severe psoriasis treated with bimekizumab: Analysis of phase 2/3 randomized trials
3. Venous thromboembolism risk is lower in patients with atopic dermatitis than other immune-mediated inflammatory diseases: A retrospective, observational, comparative cohort study using US claims data
4. Deucravacitinib, a selective, allosteric tyrosine kinase 2 inhibitor, in scalp psoriasis: A subset analysis of two phase 3 randomized trials in plaque psoriasis
5. Generalized pustular psoriasis: A consensus statement from the National Psoriasis Foundation
6. Efficacy and safety of apremilast in patients with moderate-to-severe genital psoriasis: Results from DISCREET, a phase 3 randomized, double-blind, placebo-controlled trial
7. A clinical review of structural damage in psoriatic arthritis for dermatologists: From pathogenesis to ongoing controversies
8. Psoriatic Arthritis: A Comprehensive Review for the Dermatologist. Part II: Screening and Management
9. The catch-22 of limited Food and Drug Administration approval for connective tissue disease therapies
10. Comparative safety of systemic immunomodulatory medications in adults with atopic dermatitis
11. Tralokinumab does not impact vaccine-induced immune responses: Results from a 30-week, randomized, placebo-controlled trial in adults with moderate-to-severe atopic dermatitis
12. National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: Version 2—Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments
13. Dupilumab and the risk of conjunctivitis and serious infection in patients with atopic dermatitis: A propensity score–matched cohort study
14. Axial psoriatic arthritis: An update for dermatologists
15. National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 1
16. Joint pain in patients with atopic dermatitis receiving treatment with dupilumab: A US nationwide cohort study
17. Venous thromboembolism risk is lower in patients with atopic dermatitis than other immune-mediated inflammatory diseases: A retrospective, observational, comparative cohort study using US claims data
18. EFFICACY AND SAFETY OF APREMILAST IN PATIENTS WITH MODERATE-TO-SEVERE GENITAL PSORIASIS: RESULTS FROM DISCREET, A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
19. A Clinical Review of Structural Damage in Psoriatic Arthritis for Dermatologists: From Pathogenesis to Ongoing Controversies
20. Improved sleep parallels improvements in atopic dermatitis signs, symptoms, and quality of life in adult patients treated with dupilumab: 24-week results from the DUPISTAD study
21. Use of systemic immunomodulating medications in pregnant women with atopic dermatitis: A nationwide US study
22. Achieving consensus on patient-reported outcome measures in clinical practice for inflammatory skin disorders
23. Monkeypox outbreak, vaccination, and treatment implications for the dermatologic patient: Review and interim guidance from the Medical Dermatology Society
24. Leveraging behavioral economics to promote treatment adherence: A primer for the practicing dermatologist
25. 32937 Bimekizumab treatment response is maintained up to 3 years in patients with psoriatic arthritis: Responder analyses from BE ACTIVE, a phase 2b dose-ranging study, and its open-label extension
26. 32953 Efficacy responses across disease severity and treatment history subgroups of patients with moderate to severe plaque psoriasis treated with guselkumab: Pooled results from VOYAGE 1&2 through 5 years
27. 33272 Fatigue in patients with moderate to severe plaque psoriasis treated with certolizumab pegol: Three-year results from the CIMPACT phase 3 trial
28. 34379 Bimekizumab response maintenance in high-impact areas in patients with moderate to severe plaque psoriasis: Pooled results through 96 weeks of the BE SURE, BE READY, and BE RADIANT phase 3/3b trials
29. 33006 Long-term improvement of patient-reported outcomes in adult patients with atopic dermatitis treated with baricitinib in the US and Canada
30. 33055 Guselkumab efficacy and safety through 5 years among psoriasis patients with and without metabolic syndrome at baseline: Results from VOYAGE 1 and VOYAGE 2
31. 33257 Secukinumab effects on cardiovascular risk factors in patients with psoriasis, psoriatic arthritis and axial spondyloarthritis: Results from post hoc analyses of pooled data from 19 phase 3/4 clinical studies
32. 33558 Dupilumab significantly improves sleep disturbance in adults with moderate-to-severe atopic dermatitis: Results of the DUPISTAD study
33. 33110 An analysis of fatigue in patients with psoriatic disease utilizing SF-36 vitality scores: Results through week 24 in phase 3 trials of guselkumab in patients with psoriasis and psoriatic arthritis
34. 31057 Ixekizumab treatment response: Consistency over time and at each visit in psoriatic arthritis
35. 32432 Significant nail improvement occurs as early as 24 weeks and lasts long-term through 5 years in ixekizumab treated patients with moderate-to-severe psoriasis and significant nail involvement
36. Treatment of immune checkpoint inhibitor–mediated psoriasis: A systematic review
37. 51212 The Registry of Psoriasis Health Outcomes (RePhlect): Characteristics of Early Adopters of Deucravacitinib in the North American Region
38. 51856 Spesolimab rapidly improves quality of life in patients with generalized pustular psoriasis, as per Dermatology Life Quality Index scores: Data from the Effisayil 2 trial
39. 53982 Measurement of musculoskeletal symptoms in patients with hidradenitis suppurativa: preliminary evaluation of the IDEOM MSK-Q’s content validity
40. 52244 Early Improvement in Nail and Scalp Psoriasis from a Prospective Observational Study of Patients with Psoriasis in Special Areas (PSoSA) Initiating Ixekizumab: Results from the First Interim Analysis
41. 51214 Deucravacitinib efficacy in palmoplantar and fingernail psoriasis by baseline Psoriasis Area and Severity Index (PASI) and baseline body surface area (BSA) in the phase 3 POETYK PSO-1 and PSO-2 trials
42. 51569 Bimekizumab treatment resulted in sustained improvements in nail psoriasis and signs and symptoms of psoriatic arthritis in patients with baseline nail disease: 1-year pooled results from two phase 3 studies
43. 50398 A New Tool to Improve Communication Between Hidradenitis Suppurativa Patients and Health Care Providers
44. 51898 VISIBLE: Guselkumab Demonstrates Significant Skin Clearance in Skin of Color Participants With Moderate-to-Severe Plaque Psoriasis Regardless of Baseline Inflammatory Disease Burden
45. 53954 Ratification of the IDEOM (International Dermatology Outcome Measures) MSK-Q: a new tool for measuring musculoskeletal symptoms across the psoriatic disease spectrum
46. 51109 Efficacy of deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, in scalp psoriasis by baseline Psoriasis Area and Severity Index (PASI) and baseline body surface area (BSA): A subanalysis of the phase 3 clinical trial data
47. 51609 Bimekizumab treatment resulted in sustained improvements in pain and fatigue in patients with active psoriatic arthritis and baseline psoriasis: 1-year results from two phase 3 studies
48. 51558 Bimekizumab treatment resulted in rapid and sustained improvement in total and individual Bath Ankylosing Spondylitis Disease Activity Index components in patients with psoriatic arthritis: 1-year results from two phase 3 studies
49. 52685 Bimekizumab efficacy and safety through 4 years in moderate to severe plaque psoriasis: Long-term results from the BE SURE trial and BE BRIGHT open-label extension
50. Management of psoriasis in patients with inflammatory bowel disease: From the Medical Board of the National Psoriasis Foundation
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.